Tigecycline Market Size, Share, Growth, And Industry Analysis By Type (Original Drug, Generic Drug) By Application (Hospital Pharmacies, Retail Pharmacies), Regional Forecast To 2031

Updated On: 22 April 2024

Tigecycline Market Report Overview

• 

• Request a Free Sample to learn more about this report

global tigecycline market size was USD 1445.3 million in 2021 and market is projected to touch 7597.42 Million by 2031, exhibiting a CAGR of 17.9% during the forecast period.

Tigecycline is a kind of glycylcycline with a broad spectrum of activity that inhibits protein synthesis. By attaching to the bacterial 30S ribosomal subunit, tigecycline prevents aminoacyl-tRNA from interacting with the ribosome's A site, exhibiting bacteriostatic activity. Tigecycline has also been demonstrated to have bactericidal action against isolates of S. pneumoniae and L. pneumophila.  Under the trade name Tygacil, tigecycline is an antibiotic used to treat bacterial infections that are severe, including gonorrhoea, chlamydia, acne, and urinary tract infections. For the treatment of resistant gramme positive and gramme negative infections, tigecycline is utilised as an alternate drug, particularly in individuals with a history of penicillin allergy or toxicities associated with antibiotics. Moreover, tigecycline binds to bacterial ribosomes and stops them from making the necessary cell protein for bacterial growth and multiplication, but it does not really kill bacteria. For the treatment of bacterial infections, tigecycline is administered intravenously during a 30- to 60-minute period. The initial dose is 100 mg, followed by 50 mg every 12 hours. Moreover, a 14 to 15 day course of therapy is advised for severe skin infections, and a 7 to 14 day course is advised for treating community-acquired bacterial pneumonia.

COVID-19 Impact: COVID-19 outbreak significantly disrupting the market growth

Globally, the COVID-19 pandemic has had an impact on a number of markets. Due to lockdown policies enacted by governments, pharmaceutical businesses are experiencing challenges like as regulatory modifications, changes in demand, delays in the licencing of generic medicines, disruptions in the supply chain, and product exporting restrictions. The market for tigecycline drugs worldwide is seeing negative growth.

Latest Trends

"Rising Use in Treatment Of Various Diseases Predicted To Boost Sales Prospects"

The need for antibiotics will increase due to an increase in bacterial illnesses and the advent of germs that are resistant to antibiotics. Growing elderly populations and rising prevalence rates are predicted to boost sales prospects. The European Society of Clinical Microbiology and Infection recommends tigecycline as a viable salvage treatment for difficult and serious refractory Clostridium difficile infections. Tigecycline is also used to treat cancer patients and those with impaired immune systems. Moreover, tigecycline may be used to treat acute myeloid leukaemia. Every 12 hours, tigecycline is recommended for gradual intravenous infusion. Lower doses of tigecycline must be provided to patients with poor liver function. Those with poor renal function don't require any modifications.

Tigecycline Market Segmentation

• 

• Request a Free Sample to learn more about this report

• By Type Analysis

According to type, the market can be segmented into Original Drug, Generic Drug. Original Drug is anticipated to be the leading segment.

• By Application Analysis

Based on application, the market can be divided into Hospital Pharmacies, Retail Pharmacies. Hospital Pharmacies will be the dominating segment.

Driving Factors

"Rising demand for Tigecycline For Medicines Purpose Will Fuel the Market Growth"

The demand for tigecycline medicines on the market is being driven by the rising prevalence of gonorrhoea in the U.S. For instance, the 2017 data from the Centers for Disease Control and Prevention states that there were around 555,608 cases of gonorrhoea recorded in the United States. Hence, pharmaceutical firms are concentrating on releasing treatments for therapy for bacterial infections since they are becoming more common. As an illustration, in an effort to make Tygacil (Tigecycline) injection more affordable, Sandoz Inc. introduced the AP-rated generic version of the medication in 2017. These elements are anticipated to fuel the market for tigecycline products worldwide. Tigecycline functions as an antibiotic by treating a number of bacterial illnesses. Tigecycline is a first-generation glycylcycline that is injected into the vein. The prevalence of antibiotic resistance among several bacteria, including Acinetobacter baumannii, Staphylococcus aureus, and E. coli, was a major factor in the development of tigecycline. Due to structural changes made to tigecycline, a tetracycline derivative antibiotic, its therapeutic action has been expanded to encompass both Gram-positive and Gram-negative bacteria, including those that exhibit multi-drug resistance. Throughout the course of the projected period, the market is anticipated to rise due to the rising demand for tigecycline as an antibiotic.

"Rising Frequency, Chlamydia And Gonorrhoea Have A Significant Impact On Market Growth"

Due to rising frequency, chlamydia and gonorrhoea have a significant impact in Europe. For instance, the National Health Service's 2018 report states that over 44,500 men and women under the age of 25 in England received gonorrhoea diagnoses in 2017. As a result, pharmaceutical firms are concentrating on new launches. to cure infectious disorders caused by bacteria. For instance, the European Medicines Agency authorised Accord Healthcare's request to sell tigecycline injection in February 2020 for the treatment of bacterial skin infections. Throughout the projected period, these factors are anticipated to fuel market expansion for tigecycline products globally.

Restraining Factors

"Adverse Effects Of The Antibiotic Tigecycline Restrict the Market Growth"

The adverse effects of the antibiotic tigecycline include lower back discomfort, side pain, painful or difficult urination, vision or hearing issues, coughing or hoarseness, fever or chills, and headache. In addition, there are restrictions on the use of tigecycline due to an increase in mortality from ventilator- or hospital-acquired pneumonia.

Patients often like oral amoxicillin tablets over injections of tigecycline because they are more affordable than injections for treating bacterial infections. Amoxicillin 500 mg oral tablets cost US$ 23.99, whilst tigecycline injections cost US$ 79.22. These elements are anticipated to limit the market's expansion for tigecycline goods globally. The market's expansion may be hampered by high expenses. Also, it is projected that strict government rules on medicine release may constrain the worldwide tigecycline market.

Tigecycline Market Regional Insights

• 

• Request a Free Sample to learn more about this report

"North America Region will Significantly Grow During Forecast Period "

In 2019, it is anticipated that the North American region will continue to dominate the global tigecycline market. The United States is the primary geographical area. The key factor influencing this region's supremacy is the widespread knowledge of tigecycline therapy. The market for tigecycline products is divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa based on region. Since chlamydia trachoma is so common, tigecycline is becoming more and more popular in North America. For instance, the Centers for Disease Control and Prevention (CDC) For reasons of prevention, there were 1,598,354 instances of chlamydia trachomatis infection in the U.S. in 2016, compared to 497.3 cases per 100,000 in 2015. As a result, pharmaceutical firms are concentrating on the launch of new products to treat bacterial infectious diseases. A generic version of Pfizer's tygacil with single dosage vial, Tigecycline injection, was introduced by Fresenius Kabi in the United States in 2016.

Key Industry Players

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Market Players Profiled

• Pfizer (Wyeth) (U.S.)
• Sino Biopharmaceutical (U.K.)
• Zhejiang Hisun Pharma
• Jiangsu Hansoh Pharmaceutical (U.S.)
• Abbott (U.S.)
• Natco Pharma (India)
• Lyka Labs Limited (India)
• Fresenius Kabi (Germany)
• Sandoz (Switzerland)
• APOTEX (Canada)
• Accord Healthcare (U.S.)
• Amneal Pharmaceuticals (U.S.)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.